Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB088C First-in-Human Study in Advanced Solid Tumors
NCT05652855Phase 2Not yet recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MHB088C in solid tumor, metastatic solid tumor, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Minghui Pharmaceutical, Inc.. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
MHB088C
03
Conditions
solid tumormetastatic solid tumornon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05652855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652855.